Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2010, for Genesis Biopharma, Inc. (formerly Freight Management Corp.). The company is a development-stage biopharmaceutical entity focused on the Anti-CD55 Antibody Program for treating metastatic cancers and infectious diseases. On March 15, 2010, the company consummated a merger, changed its name, and executed a 24-for-1 forward stock split. The filing notes that the company has no revenue-generating operations to date and faces substantial doubt regarding its ability to continue as a going concern without additional capital.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(152,309) | $(9,957) |
| Operating Expenses | $152,309 | $9,957 |
| Cash and Cash Equivalents (End of Period) | $209,263 | $1,154 |
| Net Cash Used in Operating Activities | $(137,893) | $(5,651) |
| Net Cash Provided by Financing Activities | $341,880 | $3,900 |
| Total Assets | $433,729 | $9,632 |
| Total Liabilities | $15,777 | $23,120 |
| Stockholders' Equity | $417,952 | $(13,488) |
Material Changes vs. Prior Period
- Significant Increase in Expenses: General and administrative expenses surged from $9,957 in the prior six-month period to $152,309. This increase is attributed to marketing, product development, SEC filing costs, and a $46,782 royalty payment for a new license agreement.
- Capital Raise: The company raised $365,000 in net proceeds from a private placement of common stock in March 2010, significantly improving liquidity from $8,257 at the start of the period to $209,263.
- Asset Acquisition: The company acquired intellectual property rights (Anti-CD55 Antibody Program) valued at $217,408, paid for via the issuance of 20,960,016 shares of common stock.
- Debt Resolution: A $23,120 liability due to a former director was partially repaid ($4,983) and the remainder ($18,137) was forgiven, recorded as miscellaneous income.
- Management Change: A change in control occurred in March 2010, with new officers and directors appointed and significant share cancellations of former management holdings.
Outlook, Risks, and Management Commentary
- Liquidity Outlook: Management estimates current cash resources ($209,263) will sustain operations for approximately six months. Additional financing via equity or debt is required to continue product development, which will likely result in shareholder dilution or increased interest expenses.
- Going Concern: The company has incurred recurring losses and negative cash flows since inception. The independent auditor has raised substantial doubt about the company's ability to continue as a going concern.
- Revenue Expectations: The company does not expect to generate significant revenue in the foreseeable future. It is dependent on licensing technologies or product sales, which are years away from commercialization.
- Risks: Key risks include the inability to secure additional funding, the failure of the Anti-CD55 program to achieve clinical milestones, and the potential for significant dilution to existing shareholders.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the six-month cash runway estimate given the high burn rate ($137,893 used in operating activities in six months).
- Valuation of IP: Review the valuation methodology for the $217,408 intellectual property acquired via stock issuance to ensure it reflects fair market value.
- Financing Terms: Investigate the terms of the private placement and any potential future financing agreements to assess dilution risks.
- License Obligations: Confirm the specific milestone triggers and royalty obligations under the agreement with Cancer Research Technology Limited.
- Related Party Transactions: Review the details of the share cancellations and the forgiveness of debt to the former director to ensure proper disclosure and valuation.